Methocarbamol oral
- Drugs List
- Therapeutic Indications
- Dosage
- Contraindications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
- Monograph
Presentation
Oral formulations of methocarbamol.
Drugs List
Therapeutic Indications
Uses
Adjunct for acute musculo-skeletal disorders with painful muscle spasm
Dosage
Adults
The recommended dose is 1500mg three to four times daily.
In severe cases up to 1500mg five times daily may be taken.
Elderly
750mg four times a day (half the maximum adult dose) or less may produce a therapeutic response.
Patients with Hepatic Impairment
The elimination half-life of methocarbamol may be prolonged in patients with chronic hepatic disease. Consider increasing the dose interval.
Contraindications
Children under 18 years
Brain damage
Coma
Epileptic disorder
Myasthenia gravis
Pre-coma
Precautions and Warnings
Elderly
Breastfeeding
Galactosaemia
Glucose-galactose malabsorption syndrome
Hepatic impairment
Lactose intolerance
Pregnancy
Renal impairment
Advise patient drowsiness may affect ability to drive or operate machinery
Some formulations contain lactose
Some products may contain soya or soya derivative
May affect results of some laboratory tests
Reduce dose in elderly
Take with sufficient water.
Pregnancy and Lactation
Pregnancy
Use methocarbamol with caution during pregnancy.
The manufacturer does not recommend using methocarbamol during pregnancy unless the potential benefits outweigh the possible hazards. At the time of writing there is limited published information regarding the use of methocarbamol during pregnancy. Although potential risks are unknown, there have been rare reports of foetal and congenital abnormalities following exposure to methocarbamol.
Lactation
Use methocarbamol with caution during breastfeeding.
The manufacturer advises caution if methocarbamol is used when breastfeeding. Animal data reports levels of methocarbamol in the breast milk, however presence in human breast milk and its effects on exposed infants are unknown.
Side Effects
Amnesia
Anaphylaxis
Angioedema
Angioneurotic oedema
Anxiety
Blurred vision
Bradycardia
Cholestatic jaundice
Confusion
Conjunctivitis
Decreased appetite
Diplopia
Dizziness
Drowsiness
Dyspepsia
Fever
Flushing
Giddiness
Headache
Hypersensitivity reactions
Hypotension
Inco-ordination
Insomnia
Jaundice
Leucopenia
Light-headedness
Metallic taste
Nasal congestion
Nausea
Nystagmus
Pruritus
Pyrexia
Rash
Restlessness
Seizures
Somnolence
Syncope
Tremor
Urticaria
Vertigo
Vomiting
Effects on Laboratory Tests
Methocarbamol may cause colour interference in certain screening tests for 5-hydroxyindolacetic acid (5-HIAA) using nitrosoaphthol reagent and in screening tests for urinary vanillymandelic acid (VMA) using the Gitlow method.
Overdosage
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Further Information
Last Full Review Date: August 2021
Reference Sources
Summary of Product Characteristics: Methocarbamol 1500mg film-coated tablets. Neuraxpharm UK Limited. Revised March 2021.
Summary of Product Characteristics: Robaxin-750. Almirall Limited. Revised July 2017.
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.